UT Health Science Center at Houston
Houston, Texas, 77030, United States
NCT Number: NCT02946021
Assessment of lymphatic structure and function pre- and post- treatment and during recovery in head and neck cancer related lymphedema patients using NIR fluorescence lymphatic imaging: Response to ICD therapy in HNC Patients.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 1 / Phase 2
Houston, Texas, 77030, United States
A non-randomized, non-blinded, single site pilot study designed to assess whether near-infrared fluorescence imaging can report on the efficacy of a pneumatic compression device to move lymph in head and neck cancer survivors with resulting head and neck lymphedema.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Pneumatic compression device cleared for use by patients who are under medical supervision for the treatment of 1) lymphedema (primary or secondary); 2) edema resulting from mastectomies, trauma, sports injuries or post immobilization; 3) venous insufficiencies; 4) wounds; and 5) stasis dermatitis, venous stasis ulcers, arterial leg ulcers and diabetic foot ulcers and treatment of head and neck lymphedema
Other names: Flexitouch system
Near-infrared Fluorescence Lymphatic Imaging following the off-label use of Indocyanine Green as a lymph contrast agent and the use of a custom designed fluorescence imager to dynamically follow lymphatic movement in subjects.
Other names: Near Infrared Fluorescence Imaging with Indocyanine Green
Time frame: Single Treatment, 2 Weeks of Treatment
Demonstrate the ability of the Flexitouch system to move lymph/enhance lymphatic uptake (indicated by increased functionality of vessels and/or changes in area of dermal backflow) as measured by Indocyanine Green (ICG) lymphography.
Time frame: Single Treatment, 2 Weeks of Treatment
Resolves dermal backflow as measured by ICG lymphography. A positive change in area indicates an increase in observable abnormal lymphatics, while a negative change indicates a decrease in observable abnormal lymphatics. A positive increase after a single treatment is expected as the manual stimulation of the lymphatics promotes the movement of ICG through the lymphatic space; however, a decrease over time provides an indication of improved lymphatic recovery.
Time frame: Single Treatment, 2 Weeks of Treatment
Alleviates lymphedema symptoms as measured by survey response.
Time frame: Single Treatment, 2 Weeks of Treatment
Flexitouch is easy to use as measured by survey responses.
Tactile Medical
Industry
Assessment of Lymphatic Structure and Function Pre- and Post- Treatment and During Recovery in Head and Neck Cancer Patients Using NIR Fluorescence Lymphatic Imaging
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03332160
Head and Neck Cancer, Head and Neck Lymphedema
Springfield, Illinois, United States
View Trial DetailsNCT05614843
Head and Neck Cancer, Head and Neck Neoplasms
Granada, Spain
View Trial DetailsNCT00496535
Head and Neck Cancer, Head and Neck Neoplasms
Chicago, Illinois, United States
View Trial DetailsNCT00496236
Head and Neck Cancer, Head and Neck Neoplasms
Chicago, Illinois, United States
View Trial Details